Terns Pharmaceuticals, Inc.

NasdaqGS:TERN Stock Report

Market Cap: US$262.9m

Terns Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:TERN Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
01 Apr 25SellUS$2,366Emil KuriakoseIndividual952US$2.49
02 Jan 25SellUS$25,607Emil KuriakoseIndividual4,481US$5.71
02 Jan 25SellUS$35,702Jill QuigleyIndividual6,240US$5.72
02 Jan 25SellUS$46,524Mark VignolaIndividual8,129US$5.72
05 Dec 24BuyUS$110,468Amy BurroughsIndividual15,450US$7.15
30 Nov 24BuyUS$11,498Melita JungIndividual2,250US$5.11
30 Nov 24BuyUS$2,606Amy BurroughsIndividual510US$5.11
12 Sep 24BuyUS$4,999,995Hongbo LuIndividual476,190US$10.50
01 Aug 24SellUS$47,148Jill QuigleyIndividual6,143US$7.68
16 Jul 24SellUS$561,640OrbiMed Advisors LLCCompany56,164US$10.00
31 May 24BuyUS$21,272Mark VignolaIndividual4,791US$4.44
31 May 24BuyUS$21,272Seokho YoonIndividual4,791US$4.44

Insider Trading Volume

Insider Buying: TERN insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of TERN?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders182,3680.208%
Hedge Funds8,167,1009.29%
VC/PE Firms20,035,27522.8%
Institutions59,498,53667.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 35%.

Top Shareholders

Top 25 shareholders own 86.25% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.35%
Soleus Capital Management, L.P.
8,167,100US$24.6m0.3%1.73%
8.66%
OrbiMed Advisors LLC
7,562,971US$22.8m0%0.36%
8.13%
Morgan Stanley, Investment Banking and Brokerage Investments
7,098,654US$21.4m112%no data
7.9%
Vivo Capital, LLC
6,895,746US$20.8m0%1.64%
6.53%
BlackRock, Inc.
5,706,632US$17.2m-0.64%no data
6.39%
Deep Track Capital, LP
5,576,558US$16.8m0%0.57%
4.93%
Schonfeld Strategic Advisors LLC
4,305,204US$13.0m-9.39%0.08%
4.75%
The Vanguard Group, Inc.
4,152,156US$12.5m7.3%no data
4.47%
Citadel Advisors LLC
3,907,887US$11.8m19.6%0.01%
3.32%
Eli Lilly Investment Consulting (Shanghai) Co., Ltd.
2,901,566US$8.7m0%1.94%
2.47%
Candriam, Société En Commandite Par Actions
2,153,969US$6.5m0%0.02%
2.26%
Acorn Bioventures
1,971,264US$5.9m0%3.97%
1.95%
Dimensional Fund Advisors LP
1,706,201US$5.1m31%no data
1.8%
Geode Capital Management, LLC
1,574,204US$4.7m3.81%no data
1.64%
Renaissance Technologies LLC
1,433,834US$4.3m130%0.01%
1.61%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
1,401,919US$4.2m-46.7%no data
1.55%
Superstring Capital Management LP
1,357,153US$4.1m-32.8%4.92%
1.52%
State Street Global Advisors, Inc.
1,324,517US$4.0m2.91%no data
1.28%
Millennium Management LLC
1,117,442US$3.4m-30.6%no data
1.1%
Parkman Healthcare Partners LLC
959,703US$2.9m15.8%0.35%
1.07%
UBS Asset Management AG
933,106US$2.8m132%no data
0.97%
Norges Bank Investment Management
849,389US$2.6m0%no data
0.93%
Bank of America Corporation, Asset Management Arm
812,042US$2.4m312%no data
0.87%
Driehaus Capital Management LLC
763,486US$2.3m-54.1%0.01%
0.8%
Integral Health Asset Management, LLC
700,000US$2.1m55.6%0.23%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/28 21:26
End of Day Share Price 2025/05/28 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Terns Pharmaceuticals, Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBMO Capital Markets Equity Research
Evan SeigermanBMO Capital Markets Equity Research
Silvan TuerkcanCitizens JMP Securities, LLC